Reference : Anticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites.
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/2268/32612
Anticorps monoclonaux a usage therapeutique en hemato-oncologie. Generalites.
French
[en] Therapeutic monoclonal antibodies in hemato-oncology
Gennigens, Christine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Collignon, Joëlle mailto [Université de Liège - ULg > > Oncologie médicale >]
Jerusalem, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Rorive, Andrée mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Sautois, Brieuc mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
2009
Revue Médicale de Liège
Hopital de Baviere
64
5-6
264-7
Yes (verified by ORBi)
National
0370-629X
Liège
Belgique
[en] Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Hematologic Neoplasms/drug therapy ; Humans
[en] For many years, chemotherapy, hormonotherapy and immunotherapy were the mainstay of cancer treatment. Recent advances in our knowledge of cell biology and particularly of cancer cell transformation, growth and metastasis have led to the identification of specific pathways playing a role in the pathophysiology of cancer. New drugs specifically developed to control these targets are collectively named "targeted therapies". Two types of targeted therapies are available: kinase (mainly tyrosine kinase) inhibitors (suffix -nib) are small molecules binding directly to the intracellular kinase domain and acting as competitive inhibitor of ATP binding and monoclonal antibodies (suffix -mab) directed towards specific cell surface receptors or their ligands to prevent receptor activation. This paper will only review monoclonal antibodies (mabs). Thirty years after their discovery mAbs have become efficient therapeutic tools. Progress in molecular engineering as well as improved knowledge of cell signalling pathways together with a better selection of the targets turned them into valuable treatments. Several mAbs are currently licensed for the treatment of hematological or solid malignancies and many others are expected in the near future.
http://hdl.handle.net/2268/32612

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Gennigens atc monoclon generalités[1].pdfPublisher postprint309.21 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.